During the corresponding time, Ultragenyx Pharmaceutical Inc recorded a revenue increase by 28.53 % year on year, sequentially revenue grew by 57.35 %. While revenue at the Ultragenyx Pharmaceutical Inc 's corporate clients
Ultragenyx Pharmaceutical Inc. has reported positive longer-term data from a Phase 3 clinical study evaluating DTX401, an adeno-associated virus (AAV) gene therapy, for the treatment of Glycogen Storage Disease Type Ia (GSDIa). This article summarizes the outcomes observed at Week 96 of the study, highlighting significant reductions in dietary cornstarch intake while maintaining stable blood glucose levels and improved fasting tolerance among participants. Glycogen Storage Disease Type Ia (GSDIa) is a rare genetic disorder characterized by the deficiency of glucose-6-phosphatase, leading to severe hypoglycemia and other metabolic complications. Traditional management strategies primarily involve dietary adj...
Investor Alert: Pomerantz Law Firm Investigates Ultragenyx Pharmaceutical Inc. Amidst Unfavourable Market Performance The Pomerantz Law Firm has initiated an investigation into claims on behalf of investors of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), in light of recent developments concerning the company’s share performance. This comes after reports indicating that Ultragenyx’s stock has lagged behind the overall market, raising concerns among its investors.Key observations reveal that throughout July 2025, shares of Ultragenyx Pharmaceutical Inc. have consistently underperformed compared to broader market indices. Investors are particularly worried as the company’s stock has shown weaker perform...
Novel Developments in Gene Therapy: Ultragenyx Updates on UX701 for Wilson Disease in Cyprus2+ Study Recent updates from Ultragenyx Pharmaceutical Inc. regarding their pivotal Phase 1/2/3 Cyprus2+ study highlight significant advancements in the development of UX701, a novel gene therapy designed for the treatment of Wilson Disease. This breakthrough comes at a crucial time for the company and reinforces the emerging potential of gene therapies to treat rare genetic disorders. Findings from the Cyprus2+ Study1. Study Overview - The Cyprus2+ study evaluates the safety and efficacy of UX701 in patients with Wilson Disease, aiming to address the challenges associated with copper metabolism due to the underl...
Ultragenyx Pharmaceuticals recently disclosed a successful outcome of their End-of-Phase 2 meeting with the US Food and Drug Administration (FDA). This crucial meeting discussed the future of Ultragenyx s GTX-102 Angelman Syndrome Program, specifically focusing on the primary endpoint for their Phase 3 study, as well as a key secondary endpoint.Interpreting the Facts: During the highlighted End-of-Phase 2 meeting, Ultragenyx Pharmaceuticals received positive news. The FDA aligned with the company on the primary endpoint of the Phase 3 study, which will evaluate patients cognitive abilities using the Bayley-4 cognition scale. This cognitive assessment tool plays a crucial role in determining the therapeutic...
In a significant leap forward in the clinical trial world, Ultragenyx Pharmaceutical Inc., a leading biopharmaceutical company in the field of rare and ultra-rare genetic diseases, announced the completion of patient enrollment in their Phase 3 Orbit and Cosmic studies. The participants in these studies are being evaluated for the treatment of Osteogenesis Imperfecta (OI) using setrusumab (UX143).Osteogenesis Imperfecta (OI), also known as brittle bone disease, is a genetic disorder that prevents the body from building strong bones. As a result, individuals with this condition can experience bones that break easily. The Orbital and Cosmic studies represent a promising step forward in researching treatments f...
Wilson Disease (WD) is a rare, genetic disorder characterized by the body s inability to properly metabolize copper, leading to its accumulation in vital organs such as the liver, brain, and other tissues. Current treatment options for WD, namely medical therapy and liver transplantation, have limitations, emphasizing the need for innovative therapeutic strategies. In this article, we delve into the exciting developments surrounding the completion of dosing across Stage 1 cohorts in the pivotal Phase 1/2/3 Cyprus2+ study, evaluating the UX701 Gene Therapy compound developed by Ultragenyx Pharmaceuticals. The much-anticipated safety and initial efficacy data from Stage 1 are expected to be released in the fir...
Ultragenyx s Evkeeza Receives Positive Recommendation for Homozygous Familial Hypercholesterolemia Treatment in the UKJanuary 4, 2024Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) has recently announced that the National Institute for Health and Care Excellence (NICE) in the UK has issued a final draft guidance recommending the use of Evkeeza (evinacumab) to NHS England. This recommendation comes as a significant development for individuals aged 12 years and older who suffer from homozygous familial hypercholesterolemia (HoFH), a rare and debilitating condition characterized by extremely high levels of low-density lipoprotein-cholesterol (LDL-C) in the blood.Evkeeza, the first-ever angiopoietin-like 3 (ANGPTL...
Sources:
Ultragenyx Pharmaceutical Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Ultragenyx Pharmaceutical Inc’s corporate clients.
For your research, we’ve provided 9 tables on Ultragenyx Pharmaceutical Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
46.73 %